Type 2 Diabetes Management With Lantus® (Malbec: Manejo Con Lantus® de Diabéticos Tipo 2) (Malbec)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00627471|
Recruitment Status : Terminated (Low recruitment in spite of strategies implemented)
First Posted : March 3, 2008
Last Update Posted : June 2, 2010
To compare in terms of HbA1c insulin naive patients with Type 2 Diabetes starting with insulin glargine on an algorithm with insulin naive patients starting with insulin glargine on the physician's standard practice.
To compare in terms of FBG insulin naïve patients starting with insulin glargine on an algorithm with insulin naïve patients starting with insulin glargine on the physician's standard practice.
To compare the percentage of patients achieving HbA1c< 7% in each treatment group.
To compare hypoglycaemic events (minor, severe and nocturnal) between groups.
To compare average insulin dose between groups.
To compare PRO (patients' reported outcomes) between groups.
To compare mean changes in body weight between treatment groups.
|Condition or disease||Intervention/treatment||Phase|
|Type 2 Diabetes||Drug: Insulin Glargine||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||9 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||A 24 Weeks, Randomized, 2 Arms, Controlled, Multi-centre, National, Open-labeled, Parallel Study in Insulin naïve Patients With Type 2 Diabetes to Compare a Lantus Titration Algorithm vs. Physician's Standard Practice|
|Study Start Date :||January 2008|
|Actual Primary Completion Date :||March 2009|
Active Comparator: A
This group must follow a defined algorithm. Only the physicians assigned to this group will know the algorithm.
Drug: Insulin Glargine
In the group following the algorithm, fasting SMBG will be asked 3 times a week until FBG<100 mg/dl is achieved. Afterwards, 1 fasting SMBG will be asked weekly. Pre-prandial SMBG will be performed at the discretion of the physician.
For the group following the algorithm, during the titration period, weekly telephone contacts will be required and a minimum of 4 visits to the clinic.
Active Comparator: B
This is the control group, following the physician's standard practice.
Drug: Insulin Glargine
For the control group (following the physician's standard practice) a minimum of 4 visits to the clinic is required. Insulin titration and concomitant medications will be done at the discretion of the physician. Strips will be distributed among patients in this group, but there will not be a requirement in frequency or type of SMBG.
- Mean difference in HbA1c (efficacy) [ Time Frame: 6 months ]
- Minor, severe and nocturnal Hypoglycaemic events (safety) [ Time Frame: from the begining of the treatment up to 5 days after the end of the study ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00627471
|Sanofi-aventis administrative office Argentina|
|Buenos Aires, Argentina|
|Study Director:||Cristian von Schulz-Hausmann||Sanofi-aventis administrative office Argentina|